[Erlotinib-induced acneiform rash not affecting previously irradiated skin].
نویسندگان
چکیده
2. Quesada A, Campos L, Rubio C, Martín MA, Herranz P, Arribas JR, et al. Tres casos de neurosíilis precoz en pacientes infectados por VIH. Actas Dermosiiliogr. 2006;97:395-9. 3. Pleimes M, Hartschuh W, Kutzner H, Enk AH, Hartmann M. Malignant syphilis with ocular involvement and organismdepleted lesions. Clin Infect Dis. 2009;48:83-5. 4. Gaudio PA. Update on ocular syphilis. Curr Opin Ophtalmol. 2006;17:562-6. 5. Kunkel J, Schürmann D, Pleyer U, Rúther K, Kneifel C, Krause L, et al. Ocular syphilis—indicator of previously unknown HIVinfection. J Infect. 2009;58:32-6. 6. Foti C, Carnimeo L, Delvecchio S, Guerriero S, Cassano N, Vena GA. Secondary syphilis with progressive ocular involvement in an immunocompetent patient. Eur J Dermatol. 2009;19:288. 7. Gass JD, Braunstein RA, Chenoweth RG. Acute syphilitic posterior placoid chorioretinitis. Ophthalmology. 1990;97:1288-97. 8. Joseph A, Rogers S, Browning A, Hall N, Barber C, Lotery A, et al. Syphilitic acute posterior placoid chorioretinitis in nonimmunocompromised patients. Eye. 2007;21:1114-9. 9. Doris JP, Saha K, Jones NP, Sukthankar A. Ocular syphilis: the new epidemic. Eye. 2006;20:703-5.
منابع مشابه
Changes in sebum levels and the development of acneiform rash in patients with non–small cell lung cancer after treatment with EGFR inhibitors
BACKGROUND It has recently been shown that patients treated with epidermal growth factor receptor (EGFR) inhibitors often develop various cutaneous adverse events. While the pathogenesis underlying these events remains unclear, the relationship between skin toxicity induced by EGFR inhibitors and the sebaceous glands that express EGFR has been previously reported. OBJECTIVES The primary aim o...
متن کاملErlotinib-induced episcleritis in a patient with pancreatic cancer.
CONTEXT Erlotinib is a relatively new anilinoquinazoline indicated for treatment of pancreatic cancer in combination with gemcitabine. It is a tyrosine kinase inhibitor that specifically targets epidermal growth factor receptor (EGFR), which is commonly overexpressed and/or mutated in solid tumors. Active competitive inhibition of adenosine triphosphate, inhibits downstream signal transduction ...
متن کاملAcneiform rash during lung cancer therapy with erlotinib (Tarceva®)
Tyrosine kinase inhibitors are currently applied in the treatment of non-small cell lung cancer with overexpressed epidermal growth factor receptor (EGFR). Acneiform rash is the earliest and most characteristic side effect of EGFR inhibition. The incidence may be as high as 50-100% of cases. We report a case of a 47-year-old patient who developed acneiform rash after 1.5 weeks of treatment with...
متن کاملPredictive blood plasma biomarkers for EGFR inhibitor-induced skin rash
Epidermal growth factor receptor overexpression in human cancer can be effectively targeted by drugs acting as specific inhibitors of the receptor, like erlotinib, gefitinib, cetuximab and panitumumab. A common adverse effect is a typical papulopustular acneiform rash, whose occurrence and severity are positively correlated with overall survival in several cancer types. We studied molecules inv...
متن کاملLeukocytoclastic vasculitis during treatment with the oral EGFR tyrosine kinase inhibitor erlotinib.
Erlotinib is a novel oral tyrosine kinase inhibitor targeting the epidermal growth factor receptor (EGFR). Skin reactions are a frequent side-effect of erlotinib therapy with various clinical manifestations such as papulo-pustular rash, xerosis, paronychia and hair changes [1]. We report two patients with advanced solid tumors who were diagnosed with a histologically confirmed cutaneous leukocy...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Actas dermo-sifiliograficas
دوره 101 2 شماره
صفحات -
تاریخ انتشار 2010